Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.50 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.50 |
| ▸ | RET | P07949 | 3/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.47 |
| ▸ | FLT3 | P36888 | 3/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.47 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.47 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.47 |
| ▸ | LTK | P29376 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.46 |
| ▸ | MERTK | Q12866 | 3/20 | 0.45 |
| ▸ | FLT1 | P17948 | 5/20 | 0.45 |
| ▸ | TEK | Q02763 | 4/20 | 0.45 |
| ▸ | KIT | P10721 | 3/20 | 0.45 |
| ▸ | FLT4 | P35916 | 3/20 | 0.45 |
| ▸ | CSF1R | P07333 | 3/20 | 0.43 |
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4265958 | 0.98 | KDR (0.49) | KDREIF2AK2RETPDGFRBFLT3 | |
| SCHEMBL4262499 | 0.94 | RET (0.51) | KDREIF2AK2RETPDGFRBFLT3 | |
| SCHEMBL4257190 | 0.93 | RET (0.47) | KDREIF2AK2RETPDGFRBFLT3 | |
| SCHEMBL4256240 | 0.93 | RET (0.50) | KDREIF2AK2RETPDGFRBFLT3 | |
| SCHEMBL4264566 | 0.92 | RET (0.46) | KDREIF2AK2RETPDGFRBFLT3 | |
| SCHEMBL4223677 | 0.91 | RET (0.51) | KDREIF2AK2RETPDGFRBFLT3 | |
| SCHEMBL4265126 | 0.90 | RET (0.46) | KDREIF2AK2RETPDGFRBFLT3 | |
| SCHEMBL4260754 | 0.90 | RET (0.46) | KDREIF2AK2RETPDGFRBFLT3 | |
| SCHEMBL4265266 | 0.90 | RET (0.47) | KDREIF2AK2RETPDGFRBFLT3 | |
| SCHEMBL4544263 | 0.90 | KDR (0.48) | KDREIF2AK2RETPDGFRBFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432714-B1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-08-06 | — | — | EP | claimed |
| US-20070293489-A1 | Substituted Pyrazolopyrimidines | ADAMS JERRY | 2007-12-20 | — | — | US | claimed |
| US-20040198751-A1 | Pyrazolo-pyrimidine compound; anticancer agents | SMITHKLINE BEECHAM CORPORATION | 2004-10-07 | — | — | US | claimed |
| US-20090029989-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES | ADAMS JERRY LEROY | 2009-01-29 | — | — | US | disclosed |
| US-20070293489-A1 | Substituted Pyrazolopyrimidines | ADAMS JERRY | 2007-12-20 | — | — | US | disclosed |
| US-20040198751-A1 | Pyrazolo-pyrimidine compound; anticancer agents | SMITHKLINE BEECHAM CORPORATION | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293489-A1 | Substituted Pyrazolopyrimidines | DPYD, TPMT, TYMP | KDR 1773/4885EIF2AK2 201/4885RET 2015/4885 |
| US-20090029989-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES | DPYD, TPMT, TYMP | KDR 1773/4885EIF2AK2 201/4885RET 2015/4885 |
| US-20040198751-A1 | Pyrazolo-pyrimidine compound; anticancer agents | DPYD, TYMP, TYMS | KDR 2070/4885EIF2AK2 248/4885RET 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.